Skip to main content
Clinical Trials/NCT01379547
NCT01379547
Unknown
Phase 3

Procalcitonin to Shorten Antibiotics Duration in ICU Patients- A China, Hong-Kong, Taiwan Multicenter Trial

National Taiwan University Hospital8 sites in 3 countries1,700 target enrollmentJune 2011
ConditionsSepsis

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Sepsis
Sponsor
National Taiwan University Hospital
Enrollment
1700
Locations
8
Primary Endpoint
Average antibiotics duration
Last Updated
13 years ago

Overview

Brief Summary

The trial is aimed to show that implementation of a procalcitonin-guided antibiotics algorithm may result in shortened antibiotics course in ICU sepsis patients without inferior outcome as compared to the conventional therapy

Detailed Description

The duration of antibiotic therapy in patients with sepsis is largely empirical. An extended treatment course for up to two weeks is a common practice for patients with sepsis in the ICU, despite lack of evidence for this duration of therapy. Procalcitonin (PCT) is a new biomarker that has high negative predictive value for systemic bacterial infection. The purpose of this trial is to evaluate whether serial PCT measurements can shorten antibiotic treatment duration in patients with sepsis in the ICU. Specific Aims 1. To show that implementation of a procalcitonin-guided antibiotics stewardship algorithm may result in shortened antibiotics course in ICU sepsis patients 2. To show that implementation of a procalcitonin-guided antibiotics stewardship algorithm may not result in inferior outcome as compared to conventional therapy

Registry
clinicaltrials.gov
Start Date
June 2011
End Date
June 2013
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients with laboratory- or image-confirmed severe infection at admission or during stay in ICU will be eligible for inclusion.
  • Definition of laboratory- or image-confirmed severe infection:
  • Two or more of four Signs of Inflammation
  • Temperature \> 38.3℃ or \< 36℃
  • Heart rate \> 90 beats/min
  • Respiratory rate \> 20 breaths/min or PaCO2 \< 32 mmHg
  • WBC \> 12,000 cells/mm3, \< 4000 cells/mm3, or \> 10% bands
  • Initial Procalcitonin \> 0.5 ng/mL
  • Presence of either laboratory or image evidence of infection
  • Laboratory evidence:

Exclusion Criteria

  • Age less than 20 years
  • Known pregnancy
  • Presence of DNR order
  • Expected ICU stay less than 3 days
  • Neutropenia (ANC count \< 500/mm3)
  • Specific infections for which long-term antibiotic treatment is strongly recommended: lung abscess or empyema, bacterial meningitis, osteomyelitis, infective endocarditis, local abscess, mediastinitis

Outcomes

Primary Outcomes

Average antibiotics duration

Time Frame: 28 days

28-day mortality rate

Time Frame: 28 days

Safety endpoints

Secondary Outcomes

  • Proportion of antibiotics use in both arms(28 days)
  • Length of ICU stay(90 days)
  • Recurrence of fever within 72 hours of antibiotics discontinuation(28 days)
  • APACHE-II score or SOFA score(28 days)
  • Reinfection between 72-hours and 28 days post antibiotics discontinuation(28 days)
  • 90-day all-cause mortality(90 days)
  • 90-day infection related readmission rate(90 days)

Study Sites (8)

Loading locations...

Similar Trials